A PHASE 1/2, RANDOMIZED, DOUBLE-BLIND, PLACEBO¿CONTROLLED SINGLE- AND MULTIPLE¿DOSE ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF VX¿670 IN ADULT SUBJECTS WITH MYOTONIC DYSTROPHY TYPE 1
- Registry ID
- VX23-670-001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- VERTEX PHARMACEUTICALS (CANADA) INCORPORATED
- Start date
- 2025-11-22
- Last update
- 2023-11-02
Conditions
Related clinical trials
- A PHASE 1, OPEN-LABEL TRIAL TO ASSESS THE SAFETY AND PHARMACOKINETICS OF MULTIPLE ASCENDING DOSES OF DT-818 IN HEALTHY VOLUNTEERS AND PARTICIPANTS WITH MYOTONIC DYSTROPHY TYPE 1
- A GLOBAL PHASE 3 OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY,
TOLERABILITY, AND EFFICACY OF INTRAVENOUS AOC 1001 FOR THE TREATMENT OF
MYOTONIC DYSTROPHY TYPE 1
- AN OPEN-LABEL EXTENSION STUDY EVALUATING SAFETY AND PHARMACOKINETICS IN
PARTICIPANTS WITH MYOTONIC DYSTROPHY TYPE 1 (FREEDOM-OLE)
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS AOC 1001 FOR THE TREATMENT OF
MYOTONIC DYSTROPHY TYPE 1
- A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-ASCENDING
DOSE STUDY OF PGN-EDODM1 IN ADULT PARTICIPANTS WITH MYOTONIC DYSTROPHY
TYPE 1 (FREEDOM2-DM1)
- A PHASE 1/2A DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ARO-DM1 IN SUBJECTS WITH TYPE 1 MYOTONIC DYSTROPHY WHO ARE 18 TO 65 YEARS
View on source registry